Home » Stocks » ALIM

Alimera Sciences, Inc. (ALIM)

Stock Price: $8.91 USD -0.17 (-1.87%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 61.62M
Revenue (ttm) 47.50M
Net Income (ttm) -7.79M
Shares Out 5.76M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE 156.25
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $8.91
Previous Close $9.08
Change ($) -0.17
Change (%) -1.87%
Day's Open 9.15
Day's Range 8.87 - 9.15
Day's Volume 2,442
52-Week Range 3.82 - 12.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic...

1 month ago - GlobeNewsWire

ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the...

2 months ago - GlobeNewsWire

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription oph...

2 months ago - GlobeNewsWire

On Wednesday, April 28, Alimera Sciences (NASDAQ:ALIM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

2 months ago - Benzinga

Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence   Amid required stay-at-home orders, many have paused or canceled doctor's appointments over the past 12 months. Rece...

2 months ago - Benzinga

ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic...

3 months ago - GlobeNewsWire

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...

3 months ago - GlobeNewsWire

ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...

4 months ago - GlobeNewsWire

Fourth Quarter Highlights:

5 months ago - GlobeNewsWire

ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic ...

5 months ago - GlobeNewsWire

Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time

5 months ago - GlobeNewsWire

ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...

5 months ago - GlobeNewsWire

Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commerciali...

5 months ago - Newsfile Corp

ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription opht...

6 months ago - GlobeNewsWire

ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...

6 months ago - GlobeNewsWire

ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis ...

7 months ago - GlobeNewsWire

ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...

7 months ago - GlobeNewsWire

ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...

8 months ago - GlobeNewsWire

ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management ...

8 months ago - GlobeNewsWire

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 75.51% and 16.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges

8 months ago - GlobeNewsWire

Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time

9 months ago - GlobeNewsWire

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the manageme...

10 months ago - GlobeNewsWire

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalm...

10 months ago - GlobeNewsWire

ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalm...

10 months ago - GlobeNewsWire

ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription o...

10 months ago - GlobeNewsWire

ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ILUVIEN receives pricing and reimbursement approvals for both diabet...

10 months ago - GlobeNewsWire

ATLANTA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi...

11 months ago - GlobeNewsWire

ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmi...

11 months ago - GlobeNewsWire

Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

11 months ago - Zacks Investment Research

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.

11 months ago - Benzinga

Second Quarter and Recent Company Highlights:

11 months ago - GlobeNewsWire

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

1 year ago - Zacks Investment Research

Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time

1 year ago - GlobeNewsWire

A randomized, controlled , multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care

1 year ago - GlobeNewsWire

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription o...

1 year ago - GlobeNewsWire

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Other stocks mentioned: CPIX, OSG, RRTS, TTNP
1 year ago - Investopedia

ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of reti...

1 year ago - GlobeNewsWire

ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments f...

1 year ago - GlobeNewsWire

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Company continues to execute on its international expansion strategy

1 year ago - GlobeNewsWire

ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the managem...

1 year ago - GlobeNewsWire

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician o... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Apr 22, 2010
CEO
Richard Eiswirth
Employees
130
Stock Exchange
NASDAQ
Ticker Symbol
ALIM
Full Company Profile

Financial Performance

In 2020, ALIM's revenue was $50.82 million, a decrease of -5.79% compared to the previous year's $53.94 million. Losses were -$5.34 million, -48.87% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 16.38, which is an increase of 83.84% from the latest price.

Price Target
$16.38
(83.84% upside)
Analyst Consensus: Strong Buy